These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 39044372)

  • 21. Nrf2 mediates the resistance of human A549 and HepG2 cancer cells to boningmycin, a new antitumor antibiotic, in vitro through regulation of glutathione levels.
    Zhang HX; Chen Y; Xu R; He QY
    Acta Pharmacol Sin; 2018 Oct; 39(10):1661-1669. PubMed ID: 30287928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perspective: Targeting the JAK/STAT pathway to fight age-related dysfunction.
    Xu M; Tchkonia T; Kirkland JL
    Pharmacol Res; 2016 Sep; 111():152-154. PubMed ID: 27241018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
    Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
    Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 25. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
    Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
    Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Characteristics of boningmycin induced cellular senescence of human tumor cells].
    Zhang XM; Gao N; Chen RX; Xu HZ; He QY
    Yao Xue Xue Bao; 2010 May; 45(5):589-94. PubMed ID: 20931760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sokotrasterol Sulfate Suppresses IFN-γ-Induced PD-L1 Expression by Inhibiting JAK Activity.
    Wang X; Xu W; Wang Z; Yu Q; Yuan L; Liu Y; Sang J; Li W; Zhu S; Jiang W; Li Z; Zhang W; Dang Y
    J Nat Prod; 2024 Apr; 87(4):713-721. PubMed ID: 38417168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Curcumin analogue EF24 prevents alveolar epithelial cell senescence to ameliorate idiopathic pulmonary fibrosis via activation of PTEN.
    Zhang Y; Liu J; Zheng R; Hou K; Zhang Y; Jia T; Lu X; Samarawickrama PN; Jia S; He Y; Liu J
    Phytomedicine; 2024 Oct; 133():155882. PubMed ID: 39096545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncogenic role of microRNA-19b-3p-mediated SOCS3 in glioma through activation of JAK-STAT pathway.
    Li T; Ge H; Yang Q; Wang J; Yin Q; Wang H; Hou G
    Metab Brain Dis; 2023 Mar; 38(3):945-960. PubMed ID: 36484970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age.
    Xu M; Tchkonia T; Ding H; Ogrodnik M; Lubbers ER; Pirtskhalava T; White TA; Johnson KO; Stout MB; Mezera V; Giorgadze N; Jensen MD; LeBrasseur NK; Kirkland JL
    Proc Natl Acad Sci U S A; 2015 Nov; 112(46):E6301-10. PubMed ID: 26578790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon-β signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells.
    Morimoto Y; Kishida T; Kotani SI; Takayama K; Mazda O
    Biochem Biophys Res Commun; 2018 Dec; 507(1-4):330-336. PubMed ID: 30446226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer.
    Zhang N; Zeng Y; Du W; Zhu J; Shen D; Liu Z; Huang JA
    Int J Oncol; 2016 Oct; 49(4):1360-8. PubMed ID: 27499357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of HDAC Inhibitor Chidamide on PD-L1 Expression in Peripheral T-Cell Lymphoma].
    Yan MM; Li ZX; Chen C; Zhang W; Zhou DB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1741-1745. PubMed ID: 36476897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TNFα-senescence initiates a STAT-dependent positive feedback loop, leading to a sustained interferon signature, DNA damage, and cytokine secretion.
    Kandhaya-Pillai R; Miro-Mur F; Alijotas-Reig J; Tchkonia T; Kirkland JL; Schwartz S
    Aging (Albany NY); 2017 Nov; 9(11):2411-2435. PubMed ID: 29176033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Downregulation of PTEN mediates bleomycin-induced premature senescence in lung cancer cells by suppressing autophagy.
    Sai X; Qin C; Wu Y; Zhao Y; Bian T
    J Int Med Res; 2020 May; 48(5):300060520923522. PubMed ID: 32436415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD-L1)-mediated immunosuppression.
    Xu Q; Long Q; Zhu D; Fu D; Zhang B; Han L; Qian M; Guo J; Xu J; Cao L; Chin YE; Coppé JP; Lam EW; Campisi J; Sun Y
    Aging Cell; 2019 Dec; 18(6):e13027. PubMed ID: 31493351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.
    Martin AM; Nirschl TR; Nirschl CJ; Francica BJ; Kochel CM; van Bokhoven A; Meeker AK; Lucia MS; Anders RA; DeMarzo AM; Drake CG
    Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):325-32. PubMed ID: 26260996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.
    Xu L; Chen X; Shen M; Yang DR; Fang L; Weng G; Tsai Y; Keng PC; Chen Y; Lee SO
    Mol Oncol; 2018 Mar; 12(3):269-286. PubMed ID: 28865178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between the expression of PD-L1 and
    Li J; Chen R; Chen Y; Xia Q; Zhou X; Xia Q; Wang C; Wan L; Bao H; Huang G; Liu J
    Br J Cancer; 2023 Aug; 129(3):541-550. PubMed ID: 37311977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppression.
    Sasi B; Ethiraj P; Myers J; Lin AP; Jiang S; Qiu Z; Holder KN; Aguiar RCT
    Leukemia; 2021 Jul; 35(7):1990-2001. PubMed ID: 33299141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.